Abstract -Optimal blood pressure (BP) targets for different populations, especially diabetics, remain uncertain after conflicting data on intensive management. We assessed whether a <120 mm Hg systolic target is beneficial and whether certain patient populations differ in response. Individual patient data of 14 094 patients from 2 randomized control trials was pooled. Seven thousand forty patients were assigned to an intensive target of <120 mm Hg and 7054 patients to a standard target of <140 mm Hg in an intention-to-treat analysis. The primary outcome was a composite of myocardial infarction, other acute coronary syndromes, stroke, heart failure, and cardiovascular mortality. Interactions between treatment and baseline characteristics were assessed. Secondary outcomes included nonfatal myocardial infarction, stroke, heart failure, cardiovascular mortality, and overall mortality. 
I n hypertension management, intensive blood pressure (BP) control to a systolic target of <120 mm Hg has been a subject of significant interest. The SPRINT (Systolic Blood Pressure Intervention Trial) established clear benefits of targeting systolic to <120 mm Hg, as compared with a <140 mm Hg standard target for a select population of older, nondiabetic, hypertensive patients at increased cardiovascular disease (CVD) risk. 1 However, the generalizability of SPRINT results to other populations is a subject of much debate. 2 In particular, intensification of antihypertensive therapy has been controversial in patients with diabetes mellitus. 3 Based on evidence derived largely from observational studies, hypertension and diabetes mellitus guidelines from the late 1990s to the early 2000s advised systolic BP targets of <130 for diabetic patients. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] However, this target was reconsidered after the publication of the ACCORD trial (Action to Control Cardiovascular Risk in Diabetes), which compared an intensive BP target of <120 mm Hg with a standard of <140 mm Hg. 19 ACCORD found no benefit in its primary outcome: a composite of nonfatal myocardial infarction (MI), nonfatal stroke, and CVD death. 19 Based on ACCORD's findings, more recent guidelines reconsidered BP targets, with the latest Joint National Committee 8 and American Diabetes Association guidelines recommending a BP target of <140/90 mm Hg for most diabetic patients. 20, 21 This discrepancy in results between ACCORD and SPRINT has generated significant discussion about proper management of the diabetic subpopulation. Hypotheses generally fall into 2 categories (1) diabetic individuals truly do respond differently to antihypertensive treatment than nondiabetics or (2) ACCORD's lower than expected event rate rendered the study underpowered to detect outcome differences. 3, 22 Ultimately, after analyzing a large body of data from randomized controlled trials (RCTs), systematic reviews, and a secondary analysis of ACCORD showing improved cardiovascular outcomes in the intensive BP/standard glycemic control group, the latest American Heart Association and American College of Cardiology guidelines (November 2017) recommended a BP target of 130/80 mm Hg in adults with diabetes mellitus.
Several meta-analyses have examined intensive BP targets in the diabetic population; one meta-analysis showed that the SPRINT and ACCORD results were consistent, 3 but others which included more trials found little to no further evidence in favor of lowering BP <130 mm Hg. [24] [25] [26] [27] [28] However, these meta-analyses have significant flaws: first, they include studies with intensive targets ranging from 120 to 150 mm Hg, which led to some trials' intensive targets overlapping with other trials' standard targets. Further, the average end-trial systolic BPs achieved by the intensive groups in meta-analytic work (eg, 133 mm Hg) often lies far >120 mm Hg intensive treatment goal of SPRINT and ACCORD. 27, 28 Current literature, including the 2017 American Diabetes Association statement on hypertension and recent meta-analytic work, has highlighted a major limitation of existing evidence: all meta-analyses examining this topic are trial-level meta-analyses that are subject to confounding and imprecise in their stratification, as opposed to individual-level meta-analyses, which are needed to best address the issue. 21 Aggregate trial-level data are inferior to individual patient data (IPD)-level analysis in that it does not allow for time-to-event analyses or detection of correlations with other individual patient characteristics. 29 Furthermore, such studies cannot account for heterogeneity based on site enrollment in trials, something that is commonly controlled for in RCT analysis of IPD. In addition, IPD-level analyses increase the power to detect differential treatment across individuals in RCTs. 30 An IPD-level analysis of ACCORD and SPRINT data, therefore, provides the most definitive answer to the debate over intensive BP management in individuals with high cardiovascular risk.
Our study is an IPD-level analysis of ACCORD and SPRINT. We selected ACCORD and SPRINT data for our analysis because they are the only RCTs that investigate a systolic BP target of 120 mm Hg. Furthermore, both trials were of high quality, enrolled similar study populations, had similar outcome measurements, and were of nearly identical design.
Our study had 3 main objectives: first, we assess whether diabetes mellitus status, which is also a marker of enrollment in the ACCORD study, causes a difference in intensive BP treatment effect. The hypothesis is that if a true difference exists, then ACCORD and SPRINT patients reacted differently to antihypertensive treatment. If there is no difference in treatment effect, then patients from both trials were responding similarly, demonstrating that diabetic and nondiabetic patients do not derive differential benefit from aggressive antihypertensive treatment. Second, we examine whether intensive BP management to a target of <120 mm Hg provides cardiovascular outcome benefits in this combined diabetic and nondiabetic population; pooling IPD from these 2 studies increases the power to detect specific cardiovascular outcome differences (eg, MI and stroke). Finally, we investigate whether other specific subpopulations responded differently to intensive BP control. By combining ACCORD and SPRINT, we present the largest IPD analysis of RCTs investigating a BP target of 120 mm Hg.
Methods
All data used to support the findings of this study are publicly available through the National Heart, Lung, and Blood Institute's BioLINCC repository and can be acquired by reasonable request at https:// biolincc.nhlbi.nih.gov/. Further particulars of analytic methods are available from the corresponding author on reasonable request.
IPD of 14 094 patients in ACCORD and SPRINT were obtained from the BioLINCC repository. 1, 19 This includes all 9361 patients in SPRINT and all 4733 patients in the ACCORD BP study.
SPRINT was a multicenter RCT that assigned patients to an intensive BP target of <120 mm Hg or a standard target of <140 mm Hg. The patients were at least 50 years old and were at increased cardiovascular risk. Patients with diabetes mellitus or prior stroke were excluded.
The ACCORD BP study was part of a multicenter, randomized 2×2 factorial design. The entire study enrolled 10 251 patients to examine intensive versus standard glycemic control, whereas the BP arm of the study assigned 4733 of the 10 251 patients to either intensive or standard BP control. The intensive and standard BP targets were the same as SPRINT. The patients all had diabetes mellitus (glycated hemoglobin of ≥7.5%), were at least 40 years old, and were at increased cardiovascular risk. Patients with a serum creatinine level >1.5 mg per deciliter were excluded. Full information on SPRINT and ACCORD are available in their original publications.
1,19
Intervention IPD of all 14 094 patients in SPRINT and the BP arm of ACCORD were pooled together. Patients were assigned their original treatment groups-a standard BP target of <140 mm Hg or an intensive target of <120 mm Hg. The standard group consisted of 7054 patients. The intensive group consisted of 7040 patients. Differences in key baseline demographics between standard and intensive groups were assessed using t tests and χ 2 tests.
Outcomes
ACCORD's primary outcome was defined as a composite of nonfatal MI, nonfatal stroke, and death from CVD, whereas SPRINT's primary outcome included these events, as well as other acute coronary syndromes and heart failure (HF). As data for all these events were available, we chose SPRINT's broader definition for our primary composite outcome, defined as a composite of nonfatal MI, other acute coronary syndromes, stroke, HF, and cardiovascular mortality. Secondary outcomes included nonfatal MI, stroke, HF, cardiovascular mortality, and overall mortality. Event rates were determined. Interaction between treatment effect and trial assignment (ACCORD versus SPRINT) was assessed to ensure the appropriateness of combining the 2 trials. As patients in ACCORD were diabetic and those in SPRINT were nondiabetic, trial status was also a marker of diabetes mellitus status.
Interactions between treatment effect and other subgroups were investigated. These subgroups included gender (male versus female), baseline CVD (yes versus no), age (<65 versus ≥65), race (white versus nonwhite), baseline systolic BP (<132, 132 to <145, and ≥145), and baseline diastolic BP (<72, 72 to <80, and ≥80).
We performed a sensitivity analysis to determine whether the high average body mass index in the pooled study was affecting our results. We did this by investigating the primary outcome rate between standard and intensive groups in the obese and nonobese subgroups. Obese was defined as a body mass index of ≥30 whereas nonobese was defined as a body mass index of <30.
We also reported pooled serious adverse events from ACCORD and SPRINT that were defined as intervention-related adverse events. These intervention-related serious adverse outcomes were defined as a composite of hypotension, syncope, and acute renal injury events.
Statistical Analysis
Analysis was by intention to treat based on the original studies. Differences in primary and secondary outcomes between the standard and intensive groups were assessed using Cox proportional hazards models. The Cox models were stratified by clinical site (SPRINT) or network of clinical sites (ACCORD). Stratifying by clinical site or network allowed us to ensure that the model was also stratified by trial assignment (SPRINT or ACCORD), to control for confounding effects of trial assignment. The proportional hazards assumption was assessed. Differences between standard and intensive groups were compared using the likelihood-ratio test with 2-sided P values. For each outcome, event rates were determined by taking into account censoring of the data. Subgroup analysis was performed by comparing 2 nested models: one included treatment effect and subgroup assignment and the other included an additional term representing the interaction between treatment and subgroup. Analysis of deviance was used to calculate the P value of interaction. Significance threshold for outcomes and interactions was 0.05.
Differences in intervention-related serious adverse events between intensive and standard groups were compared using a χ 2 test for independence.
All statistical analysis was done with R statistical computing software. This study was reviewed by the Boston University Medical Campus institutional review board and determined to be not human subjects research. All data analyzed in this study is available through the National Heart, Lung, and Blood Institute's BioLINCC repository.
Results

Study Participants
No statistically significant differences in age, sex, baseline systolic BP, or baseline diastolic BP between standard and intensive groups were found (P values: 0.99, 0.50, 0.71, and 0.60, respectively). Participants had an average age of 66.0 and were 61.3% male and 58.6% white. Mean baseline BP was 139.5/77.4 mm Hg, and average body mass index was 30.5. Nearly half (44.4%) had never smoked, whereas only 13.2% were current smokers (Table 1) . SPRINT and ACCORD participants differed in certain baseline characteristics. SPRINT's population was ≈6 years older (67.9 versus 62.2) and had fewer female participants (35.6% versus 47.7%) and non-Hispanic whites (57.7% versus 60.5%). Baseline systolic (139.7 versus 139.2 mm Hg) and diastolic (78.1 versus 76.0 mm Hg) BPs were comparable between the 2 trials.
Blood Pressure
Changes in BP were observed shortly after patient induction in the trials. After 1 year of treatment, average BP measurements were 121.8±14.7 mm Hg for the intensive group and 134.8±14.0 mm Hg for the standard group. At study end time, average systolic BP reached 120.3±14.6 mm Hg (intensive) and 134.1±14.3 mm Hg (standard). Patients with follow-up time ≤1 year were excluded from these calculations.
Outcomes
The primary outcome rate was significantly decreased within the intensive group (hazard ratio [HR], 0.83; 95% confidence interval [CI], 0.74-0.92; P<0.001; Figure 1 Baseline characteristics for participants in the pooled sample. Intensive therapy patients were assigned a systolic blood pressure (SBP) target of <120 mm Hg and standard therapy patients were assigned a target of <140 mm Hg. DBP indicates diastolic blood pressure; and GFR, glomerular filtration rate. management. Comparisons between our overall pooled study and ACCORD/SPRINT are available in Figure 2 .
Diabetes mellitus status and treatment effect had no significant interaction (P=0.156). As diabetes mellitus status is also a marker of enrollment in SPRINT or ACCORD, no interaction with treatment effect was observed between trial enrollment and treatment effect.
No significant interactions between treatment effect and baseline age, sex, race, CVD history, systolic BP, or diastolic BP were observed (P values: 0.40, 0.95, 0.54, 0.18, 0.86, and 0.67, respectively; Figure 3) .
The decreased primary outcome rate with intensive management was observed in both nonobese and obese subgroups (P=0.0225 and P=0.0103, respectively).
The intensive group had 269 patients (3.97%) with intervention-related serious adverse events and 6771 without. The standard group had 106 (1.53%) patients with interventionrelated serious adverse events and 6948 without. The difference between intensive and standard groups was statistically significant (P<0.001).
Discussion
Intensive management to a goal of <120 mm Hg demonstrated a 17% reduction in composite cardiovascular outcomes compared with standard management. This is in line with prior meta-analyses demonstrating the cardiovascular benefit of intensive targets, as well as the recent American College of Cardiology/American Heart Association guidelines. 24, 26, 31 At the 1-year mark, the difference between the average BP in the standard (134.4 mm Hg) and intensive (121.8 mm Hg) groups was substantial (13 mm Hg). This difference is a major strength of our study as compared with prior meta-analyses, which had small or overlapping differences between the 2 groups. 27, 28 Although the intensive group demonstrated cardiovascular benefits with intensive management, this was at the increased risk of intervention-related adverse outcomes (intensive, 3.97%; standard, 1.53%). Thus, the benefits of intensive BP targets need to be weighed against the increased risk of intervention-related adverse outcomes.
We found no evidence of an interaction between treatment effect and trial, suggesting that the nondiabetic patients of SPRINT and the diabetic patients responded similarly to intensive BP management. Prior meta-analytic work supports this conclusion, and the 17% reduction observed within this study falls well within the CI observed in ACCORD (0.73-1.06). Together, these findings support the interpretation that ACCORD's lower than expected event rate limited its power to detect a difference in primary outcome. 24, 26, 31 Current guidelines have been hesitant to adopt BP targets <140 mm Hg, especially for diabetic patients. 20, 32, 33 Newer recommendations have acknowledged that intensive targets may be beneficial for specific patients; however, such recommendations provide little guidance on which patients would benefit from such treatment. 21, 32 Future recommendations should acknowledge that such benefits likely exist in a broader array of patients, specifically diabetic patients. 2, 3 Our pooled analysis increased the power to detect secondary outcomes. For example, more overall mortality No. of events in the intensive and standard treatment groups. Primary outcome was a composite of myocardial infarction (MI), other acute coronary syndromes, stroke, heart failure, and cardiovascular mortality. P values of <0.05 were considered significant. CI indicates confidence interval; and HR, hazard ratio. events (659) occurred in our study than did composite outcome events in either SPRINT or ACCORD individually (562 and 445). All secondary outcomes were reduced in the intensively managed group compared with the standard group, though only stroke and HF showed statistical significance. The stroke reduction benefit is in concordance with prior meta-analytic work showing a protective effect of intensive BP management. 34 Similarly, other studies observed an association between high BPs (increased afterload) and worsening left ventricular hypertrophy, a risk factor for HF. 35 Baseline age, sex, race, systolic BP, diastolic BP, and CVD history did not interact with treatment effect, indicating that the cardiovascular benefit occurred regardless of a wide variety of baseline characteristics. Although various subgroup analyses of SPRINT and ACCORD exist, 36 subgroup analyses of this type are often underpowered to detect differences. 37 Treatment interaction effects observed in large population studies, such as ours, serve as better markers of treatment effect than individual subgroups. 38 One possible criticism relates to the disparate size of the pooled trials; specifically, even if there were a true difference in treatment effect between the trials, SPRINT's positive result might simply overpower ACCORD's null result in the pooled analysis because of SPRINT being twice as large. However, although SPRINT was a much larger trial, ACCORD participants in fact had more primary outcome events than the SPRINT participants (694 in ACCORD versus 562 in SPRINT), a factor which would act to mitigate the effect of the disparate trial sizes on the analysis.
Our study has limitations. ACCORD and SPRINT both used automated BP measurements, which tend to be lower than standard nonautomated office readings; therefore, our results must be interpreted in the context of these differences. 21 Next, given that SPRINT enrolled only nondiabetic patients, and ACCORD enrolled only diabetic patients, it was impossible to separate diabetes mellitus status from other factors associated with trial assignment. Our study only included data from 2 trials, as these were the only RCTs which have investigated an intensive SBP target of 120 mm Hg. As such, the results of our study are limited by the inclusion criteria (patients with increased CVD risk) of these original studies. We could not address the effects of obstructive sleep apnea, which can elevate BP and commonly cooccurs with hypertension.
Perspectives
Our study is the largest IPD analysis of RCT data investigating a BP target of 120 mm Hg, consisting of 2 studies with the same intensive BP target, similar achieved end-study BP, and nearly identical design. We demonstrate that an intensive BP target of 120 mm Hg reduces rates of cardiovascular outcomes and that this benefit extends to diabetic patients. The cardiovascular benefits from intensive BP control are independent of baseline age, sex, race, systolic BP, diastolic BP, and CVD history. Future study should examine intensive targets in populations that are not at increased cardiovascular risk, as this study included only those that were. The breadth of patients that may benefit from intensive BP control should motivate clinicians and guideline writers to broaden the groups that intensive control is recommended for. Targets of <120 mm Hg systolic can be beneficial for a wide variety of patients.
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